Do MannKind Corporation(NASDAQ:MNKD), Regado Biosciences Inc(NASDAQ:RGDO), and Sangamo Biosciences, Inc.(NASDAQ:SGMO) Have Strong Long-Term Outlooks?

Posted by Saimoon October 5, 2014 0 Comment 2365 views


New York, NY – GDP INSIDER  –  10/06/2014.

This article discusses three biopharamceutical companies: MannKind Corporation, Regado Biosciences, and Sangamo Biosciences.

MannKind Corporation(NASDAQ:MNKD) is a California-based biopharmaceutical company that develops and commercializes therapeutic products for the treatment of diabetes and cancer. The company announced Oct. 3rd that it had received a $150 million upfront payment from Sanofi for the development and commercialization of the Afreezza(R) Inhalation Powder, an insulin therapy that would be used to treat adults with both type 1 and type 2 diabetes. The company is currently situated $1.72 above and $5.96 below its 52 week low and high of $3.80 and $11.48, respectively.

Will Mankind Continue To Build Its Portfolio Of Products? View Our Free MNKD Analysis.

On Sept. 24th, Regado Biosciences Inc(NASDAQ:RGDO) announced that it would be reducing its workforce by 60%, a percentage that equals twenty employees across all of the company’s operational sites. The New Jersey-based company determined that the reduction will result in restructuring charges totaling around $2 million. The company’s workforce reduction, in conjunction with the end of the enrollment process for its phase III study of REGULATE-PCI, should result in decreased expenditures for the company.

Will Regado’s Recent Changes Pay Off? Receive A Free RGDO Analysis.

The California-based Sangamo Biosciences, Inc.(NASDAQ:SGMO) is a clinical stage biopharmaceutical company that researches and develops zinc finger DNA-binding proteins for gene regulation and gene modification. The company currently has a bid price of $10.41 x 200 and an offer price of $11.88 x 500, a liquid combination for Sangamo Biosciences. The company anticipates that it will be submit an investigation new drug application for the treatment of hemophilia B in the second quarter of 2015.

Should You Wait Until The Second Quarter 2015 To Invest In Sangamo? Take A Look At Our Free SGMO Analysis.

About HotStockGains

HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment